Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

four seasons agribusiness pty ltd - glyphosate present as the isopropylamine salt; polyethanoxy (15) tallow amine - aqueous concentrate - glyphosate present as the isopropylamine salt glycine active 450.0 g/l; polyethanoxy (15) tallow amine emulsifiers & surfactants other 120.0 g/l - herbicide

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, concentrated - excipient ingredients: hydrogenated soy phosphatidylcholine; histidine; hydrochloric acid; ammonium sulfate; cholesterol; water for injections; sodium hydroxide; sodium methoxy peg-40-carbonyl-distearoylphosphatidylethanolamine; sucrose - indications: for the treatment of: (1) advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. (2) aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/cubic mm) and extensive mucocutaneous or visceral disease. as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). indications as at 29 february 2008: caelyx, as monotherapy, is indicated for the treatment of metastatic breast cancer. caelyx is also indicated for the treatment of: advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. caelyx may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). caelyx is also indicated, in combination with bortezomib, for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or who are unsuitable for bone marrow transplant.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - doxorubicin hydrochloride, quantity: 2 mg/ml - injection, concentrated - excipient ingredients: ammonium sulfate; histidine; water for injections; sodium hydroxide; cholesterol; sodium methoxy peg-40-carbonyl-distearoylphosphatidylethanolamine; sucrose; hydrogenated soy phosphatidylcholine; hydrochloric acid - for the treatment of aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/mm) and extensive mucocutaneous or visceral disease. caelyx may be used for first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). indications as at 21 september 2001: for the treatment of: (1) advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. (2) aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/cubic mm) and extensive mucocutaneous or visceral disease. as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). indications as at 29 february 2008: caelyx, as monotherapy, is indicated for the treatment of metastatic breast cancer. caelyx is also indicated for the treatment of: advanced epithelial ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. aids-related kaposi's sarcoma (ks) in patients with low cd4 counts (<200 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. caelyx may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or other anthracycline). caelyx is also indicated, in combination with bortezomib, for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or who are unsuitable for bone marrow transplant.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

randlab australia pty ltd - oxytetracycline as oxytetracycline hydrochloride - parenteral liquid/solution/suspension - oxytetracycline as oxytetracycline hydrochloride antibiotic active 100.0 mg/ml - antibiotic & related

Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - lauromacrogol 400, quantity: 60 mg - injection, solution - excipient ingredients: ethanol; dibasic sodium phosphate dihydrate; monobasic potassium phosphate; water for injections - indications: the solutions are indicated for the treatment of varicose veins (up to 6mm diameter) of the lower limbs by compression sclerotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - lauromacrogol 400, quantity: 40 mg - injection, solution - excipient ingredients: ethanol; dibasic sodium phosphate dihydrate; monobasic potassium phosphate; water for injections - indications: the solutions are indicated for the treatment of varicose veins (up to 6mm diameter) of the lower limbs by compression sclerotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - lauromacrogol 400, quantity: 20 mg - injection, solution - excipient ingredients: ethanol; dibasic sodium phosphate dihydrate; monobasic potassium phosphate; water for injections - indications: the solutions are indicated for the treatment of varicose veins (up to 6mm diameter) of the lower limbs by compression. sclerotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - lauromacrogol 400, quantity: 10 mg - injection, solution - excipient ingredients: ethanol; dibasic sodium phosphate dihydrate; monobasic potassium phosphate; water for injections - indications: the solutions are indicated for the treatment of varicose veins (up to 6mm diameter) of the lower limbs by compression sclerotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - morphine hydrochloride trihydrate, quantity: 10 mg/ml - injection, solution - excipient ingredients: water for injections; dilute hydrochloric acid - - short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. - symptomatic relief of severe and intractable pains in terminal cancer patients. - use as a pre-operative medication and as an analgesic adjunct in general anaesthesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - morphine hydrochloride trihydrate, quantity: 10 mg/ml - injection, solution - excipient ingredients: dilute hydrochloric acid; water for injections - - short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain. - symptomatic relief of severe and intractable pains in terminal cancer patients. - use as a pre-operative medication and as an analgesic adjunct in general anaesthesia.